We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RACE:MILFerrari NV Analysis

Data as of 2026-06-18 - not real-time

€310.70

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Ferrari shares are trading at €310.7, comfortably above the 20‑day (€302.66) and 50‑day (€297.94) simple moving averages but still below the 200‑day average (€325.42), indicating a short‑term bullish bias within a longer‑term neutral framework. The MACD line sits at 5.65 above its signal (4.09), generating a bullish signal, while the RSI at 56 points suggests the stock is neither overbought nor oversold. Volatility is elevated at roughly 40% over the past 30 days, yet the beta of 0.33 points to low systematic risk, and the price is holding above the identified support of €281.5 with resistance near €323.3.
Fundamentally, Ferrari delivers premium profitability—gross margin of 51.6%, operating margin of 29.5% and a net profit margin of 22.2%—and an impressive ROE of 41.9%, underscoring capital efficiency. The dividend yield of 1.13% is backed by a modest 33% payout ratio, indicating sustainability. Although the trailing PE of 34.6 and PB of 13.5 suggest a premium valuation, analyst consensus projects a median target of €380, implying roughly a 22% upside, and the DCF‑derived fair value (though anomalously low) further flags potential mispricing.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD with price above short‑term SMAs
  • Approaching resistance level near €323.3
  • Decreasing volume and high 30‑day volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst median price target of €380 (~22% upside)
  • Strong profitability metrics and ROE
  • Sustainable dividend with healthy payout ratio

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Iconic brand with durable demand in luxury performance segment
  • Consistently high margins and cash flow generation
  • Low beta indicating resilience to broader market swings

Key Metrics & Analysis

Financial Health

Revenue Growth3.20%
Profit Margin22.19%
P/E Ratio34.6
ROE41.97%
ROA13.08%
Debt/Equity72.25
P/B Ratio13.5
Op. Cash Flow€2.4B
Free Cash Flow€985.9M

Technical Analysis

TrendNeutral
RSI56.0
Support€281.50
Resistance€323.30
MA 20€302.66
MA 50€297.94
MA 200€325.42
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

Fair Value€79.03
Target Price€371.03
Upside/Downside19.42%
GradeFair
TypeBlend
Dividend Yield1.13%

Risk Assessment

Beta0.33
Volatility40.07%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.